Table 3 Complications and treatments of COVID-19 patients with cardiac injury.
From: Key factors leading to fatal outcomes in COVID-19 patients with cardiac injury
Characteristic | No. (%) | |||
|---|---|---|---|---|
Total (N = 173) | Nonsurvivors (N = 87) | Survivors (N = 86) | p value | |
Complications | Â | Â | Â | Â |
 Acute liver injury | 31 (17.9%) | 21 (24.1%) | 10 (11.6%) | .032 |
 Acute kidney injury | 65 (37.6%) | 42 (48.3%) | 23 (26.7%) | .003 |
 Heart failure | 130 (75.1%) | 68 (78.2%) | 62 (72.1%) | .356 |
 Coagulopathy | 66 (38.2%) | 45 (51.7%) | 21 (24.4%) | < .001 |
 ARDS | 91 (52.6%) | 68 (78.1%) | 23 (26.7%) | < .001 |
Treatments | Â | Â | Â | Â |
 Antiviral therapy | 147 (85.0%) | 71 (81.6%) | 76 (88.4%) | .213 |
 Antibiotic therapy | 148 (85.5%) | 79 (90.8%) | 69 (80.2%) | .048 |
 Corticosteroid | 117 (67.6%) | 66 (75.9%) | 51 (59.3%) | .020 |
 Immunoglobulin | 130 (75.1%) | 71 (81.6%) | 59 (68.6%) | .048 |
 Vasoconstrictive agents | 75 (43.4%) | 58 (66.7%) | 17 (19.8%) | < .001 |
 Continuous renal replacement therapy | 31 (17.9%) | 20 (23.0%) | 11 (12.8%) | .080 |
Oxygen support | Â | Â | Â | Â |
 Nasal cannula | 137 (79.2%) | 80 (92.0%) | 57 (66.3%) | < .001 |
 Noninvasive ventilation or high-flow nasal cannula | 85 (49.1%) | 56 (64.4%) | 29 (33.7%) | < .001 |
 Invasive mechanical ventilation or ECMO | 28 (16.2%) | 16 (18.4%) | 12 (14.0%) | .428 |
